Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01027377 · ClinicalTrials.gov registry record · Phase 1
Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A
A Phase 1 study, sponsored by Bioverativ Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01027377 is a Phase 1 study that has completed, run by Bioverativ Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT01027377, a Phase 1 study, has completed, sponsored by Bioverativ Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The study is to investigate the safety, tolerability, and pharmacokinetics (the determination of the concentration of the administered drug in blood over time) of recombinant Factor VIII Fc fusion protein (rFVIIIFc) in previously-treated subjects with severe hemophilia A.
Interventions
- DRUG rFVIIIFc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-12 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01027377
The ClinicalTrials.gov registry entry for NCT01027377 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bioverativ Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rFVIIIFc is the first listed.
NCT01027377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01027377 about?
NCT01027377 is a clinical study titled "Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A". The study is to investigate the safety, tolerability, and pharmacokinetics (the determination of the concentration of the administered drug in blood over time) of recombinant Factor VIII Fc fusion protein (rFVIIIFc) in previously-treated subjects with severe hemophilia A.
What is the current status of trial NCT01027377?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-12. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01027377?
The interventions under investigation include: rFVIIIFc (DRUG).
Who is sponsoring clinical trial NCT01027377?
This trial is sponsored by Bioverativ Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.